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S U M M A R Y
Objectives: To describe the incidence, mortality, cost, and length of stay (LOS) of hospitalized
community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in three Southeast
Asian countries: Malaysia, Indonesia, and the Philippines.
Methods: Using Casemix system data from contributing hospitals, patients with International
Classiﬁcation of Diseases 10th revision (ICD-10) codes identifying pneumonia were categorized into
CAP or HAP using a logical algorithm. The incidence among hospitalized patients, case fatality rates
(CFR), mean LOS, and cost of admission were calculated. The population incidence was calculated based
on Malaysian data.
Results: For every 100 000 discharges, CAP and HAP incidences were 14 245 and 5615 cases,
respectively, in the Philippines, 4205 and 2187, respectively, in Malaysia, and 988 and 538, respectively,
in Indonesia. The impact was greatest in the young and the elderly. The CFR varied from 1.4% to 4.2% for
CAP and from 9.1% and 25.5% for HAP. The mean LOS was 6.1–8.6 days for CAP and 6.9–10.2 days for HAP.
The cost of hospitalization was between USD 254 and USD 1208 for CAP and between USD 275 and USD
1482 for HAP.
Conclusions: The burden of CAP and HAP is high. Results varied between the three countries, likely due to
differences in socio-economic conditions, health system differences, and ICD-coding practices.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pneumonia is a signiﬁcant problem worldwide and remains one
of the major causes of death among children younger than 5 years
old.1,2 In 2010, it was estimated that there were 120 million
episodes of pneumonia globally, and 1.3 million episodes led to* Corresponding author.
E-mail address: soraya.azmi@azmi-burhani.com (S. Azmi).
http://dx.doi.org/10.1016/j.ijid.2016.05.021
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).death among children in this age group in 2011.3,4 The elderly and
adults with pre-existing medical conditions are also at increased
risk of pneumonia. These include people with chronic heart, lung,
or liver disease, people living with HIV, and those who have had
transplants or are taking immunosuppressive drugs.5
Hospitalizations for pneumonia may be classiﬁed based on the
location of prior exposure and can be categorized as hospital-
acquired or community-acquired. In contrast to community-
acquired pneumonia (CAP), hospital-acquired pneumonia (HAP)
occurs more than 48 h after a hospital admission without anyciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
S. Azmi et al. / International Journal of Infectious Diseases 49 (2016) 87–9388antecedent signs at the time of admission.6,7 By pathogen, HAP and
CAP differ. Pathogens causing CAP are commonly Streptococcus
pneumoniae, Mycoplasma pneumoniae, Chlamydophila pneumoniae,
Legionella pneumophila, Haemophilus inﬂuenzae type B, and
respiratory syncytial virus (RSV).8,9 In some countries in the Asia
Paciﬁc, Klebsiella pneumoniae is also a common CAP pathogen.9
Common HAP-causing pathogens include Pseudomonas aeruginosa,
Escherichia coli, K. pneumoniae, and Acinetobacter species, while
Staphylococcus aureus is an increasing problem.7 HAP-causing
bacteria are considered to be more virulent since many are likely to
be multidrug-resistant.5–7 The rates of morbidity and mortality
also tend to differ between CAP and HAP. Hence, being able to
differentiate between CAP and HAP is of interest to clinicians and
researchers.
Few studies have compared the incidences of the two pneumonia
types. One such study was conducted in the region of Lazio in Italy
and explored the incidences of CAP, HAP, and AIDS-related
pneumonia using hospital information system data.10 The annual
incidence rates of the three pneumonia types were found to be 159,
75, and 7.4 per 100 000 population, respectively; meanwhile, the
fatality rates were 9.4%, 29.3%, and 11.2%, respectively.
Few studies from the Asia-Paciﬁc region have reported
pneumonia incidence. Most studies have tended to focus on the
causative organisms, antibiotic resistance, or risk factors.9,11
Furthermore, few countries have reported incidence rates.12
Among the estimates available is one from Thailand, which
reported incidence as being between 177 and 580 per 100 000 pop-
ulation.13,14 In another study performed in central Vietnam, the
incidence of CAP was estimated at 0.81 per 1000 population.15 In
Singapore, a national study showed that the incidence of
pneumococcal pneumonia was approximately 4.5 per 100 000 in
those aged 15–64 years.16 No study has explored the difference in
incidence of CAP and HAP in Southeast Asian countries.
Information on cost or the economic burden is relatively limited
and does not discuss these two pneumonia categories. A study of
pneumonia admission costs in Singapore estimated a cost of USD
1294 for a hospital admission of 6.4 days and USD 3456 for a
hospital admission of 10 days.17 In the Philippines, it was
estimated that the cost of hospitalization with moderate-risk
CAP was between USD 852 and 2678.18 On the other hand, the cost
of pneumonia in rural Thailand was reported to be lower, varying
from USD 490 to 628.13Within the wider Asian region, the cost per
hospital admission was reported to be USD 3221 among elderly
patients in Taiwan, while the total annual burden in the elderly
was USD 1 897 137.19 Also in Taiwan, a study by Wu et al. found
that the cost of pneumococcal pneumonia hospitalization in older
adults aged 50 years and above was between NT$ 153 000 and
178 000 (USD 5109–5952) and the total annual cost was greater
than NT$ 3.6 billion (USD 112 023 220).20
In developed countries, administrative databases have been
used widely to understand disease patterns and burden of disease.Table 1
ICD-10 codes used to identify cases of pneumonia
Deﬁnition 
Inﬂuenza due to identiﬁed inﬂuenza virus 
Inﬂuenza, virus not identiﬁed 
Viral pneumonia, not elsewhere classiﬁed 
Pneumonia due to Streptococcus pneumoniae 
Pneumonia due to Haemophilus inﬂuenzae 
Bacterial pneumonia, not elsewhere classiﬁed 
Pneumonia due to other infectious organisms, not elsewhere classiﬁed
Pneumonia in disease classiﬁed elsewhere 
Pneumonia, organism unspeciﬁed 
ICD, International Classiﬁcation of Diseases.Such studies have been performed in the USA and Europe where
administrative databases are readily available and are well-
established.21–27 In Asia, research using administrative databases
is less common, except in South Korea, Taiwan, and Japan.27,28
Although administrative data are not initially collected for
research, they can provide useful information in a less resource-
intensive manner by eliminating the need for primary data
collection.27 Two such studies exploring pneumonia are the
studies mentioned above by Wu et al.,20 and Low et al.,16
performed in Taiwan and Singapore, respectively.
Although research using administrative databases is still new in
Southeast Asia, pockets of data exist that can be used for
epidemiological research.27,28 One of these sources of data is the
administrative system developed by the United Nations University
International Institute for Global Health (UNU-IIGH) and the
National University of Malaysia.27,29,30 The system, called Casemix,
has been in use at the medical center of the National University of
Malaysia since 2002 and was implemented in a second Malaysian
academic center in 2012. Meanwhile, the Casemix system has been
used on a larger scale in Indonesia and the Philippines,31 since
2008 and 2009, respectively, to support the implementation of
their social insurance systems. Hospital discharge data are coded
using the International Classiﬁcation of Diseases 10th revision
(ICD-10) and diagnosis-related groups (DRGs). The system
contains costs of ambulatory services, in-patient services, daycare
surgery, and other services. In Indonesia and the Philippines, it is
used for hospital reimbursement by the relevant social health
insurance authorities in each country. Social insurance has not
been implemented in Malaysia; the Casemix system is used in two
hospitals for budgeting and academic purposes in this country.
The objectives of this study were to describe the incidence,
mortality, and resource utilization associated with hospitalized
pneumonia in Malaysia, Indonesia, and the Philippines using
Casemix data, as well as to better understand the differences
between CAP and HAP. It was aimed to elucidate the incidences of
CAP and HAP among hospitalized patients, as well as to ascertain
the differences in cost, length of stay (LOS), and prevalence of
comorbidities between CAP and HAP.
2. Methods
Casemix system data from hospitals in Malaysia, Indonesia, and
the Philippines that were contributing to the dataset at the time of
the study were utilized. In Indonesia, hospitals began to use the
system in January 2014 to implement social insurance for citizens
in the lower socio-economic groups. In the Philippines, coverage of
hospitals was limited at the time of the study and was made
possible through collaboration between UNU-IIGH, the National
University of Malaysia, the Department of Health of the
Philippines, and the Ministry of Health of Indonesia. The available
dataset for this study consisted of data from 42 anonymizedICD-10 code
J10.0, J10.1, J10.8
J11.0, J11.1, J11.8
J12.0, J12.1, J12.2, J12.3, J12.8, J12.9
J13
J14
J15.0, J15.1, J15.2, J15.3, J15.4, J15.5, J15.6, J15.7, J15.8, J15.9
 J16.0, J16.8
J17.0, J17.1, J17.2, J17.3, J17.8
J18.0, J18.1, J18.2, J18.8, J18.9
Table 2
ICD-10 codes used to identify comorbidities
Deﬁnition ICD-10 code
Diabetes E10.0–E10.9, E11.0–E11.9, E12.0–E12.9, E13.0–E13.9, E14.0–E14.9
Lung disease I26.0, I27.0, I27.8, I27.9, I28.0, I28.8, I28.9, J40, J41.0, J41.1, J41.8, J43.0, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.8, J44.9, J45.0, J45.1,
J45.8, J45.9, J46, J47, J61, J62.0, J62.8, J63.0, J63.1, J63.2, J63.3, J63.4, J63.5, J63.8, J66.0, J66.1, J66.2, J66.8, J67.0, J67.1, J67.2, J67.3, J67.4,
J67.5, J67.6, J67.7, J67.8, J67.9, J68.4, J70.1, J70.3
Chronic liver disease B18.0, B18.1, B18.2, B18.8, B18.9, E52, F10, G62.1, I42.6, I85.0, I85.9, I86.4, I98.2, K29.2, K70.0, K70.3, K70.9, K71.1, K71.3–K71.5, K71.7,
K72.0, K72.1, K72.9, K73.0, K73.1, K73.2, K73.8, K73.9 K74.0, K74.1, K74.2, K74.3, K74.4, K74.5, K74.6, K76.0, K76.2–K76.9, T51.0, T51.1,
T51.2, T51.3, T51.8, T51.9, Z50.2, Z71.4, Z72.1, Z94.4
Immunodeﬁciency B20.0, B20.1, B20.2, B20.3, B20.4, B20.5, B20.6, B20.7, B20.8, B20.9, B21.0, B21.2, B21.3, B21.7, B21.8, B21.9, B22.0, B22.1, B22.2, B22.7,
B24, C81.0– C85.9, C88.0–C96.9, C90.0, C90.2, C77.0– C80.9, C00.0–C26.9, C30.0–C34.9, C37–C41.9, C43.0, C45.9–C58, C60.0–C76.8, C97,
Q89.01, Q89.09
Cardiovascular disease A52.0, I09.9, I10, I05.0–I08.9, I09.1, I09.8, I11.0–I13.9, I11.0, I13.0, I13.2, I15.0, I15.1, I15.2, I15.8, I15.9, I25.5, I34.0–I39.8, I42.0,
I42.5–I42.9, I43.0, I143.1, I143.2, I143.8, I44.1–I44.3, I45.6, I45.9, I47.0–I49.9, I50.0, I70.0, I71.9, I73.1, I73.8, I73.9, I77.1, I79.0,
I79.2, K55.1, K55.8,
K55.9, P29.0, R00.0, R00.1, R00.8, T82.1, Q23.0–Q23.3, Z45.0, Z95.0, Z95.2–Z95.4, Z95.8, Z95.9
Renal disease I12.0, I13.1, N18.1, N18.2, N18.3, N18.3, N18.4, N18.5, N18.9, N25.0, Z49.0–Z49.2, Z94.0, Z99.2
ICD, International Classiﬁcation of Diseases.
S. Azmi et al. / International Journal of Infectious Diseases 49 (2016) 87–93 89private and public hospitals in Indonesia, 18 hospitals in the
Philippines, and two academic hospitals in Malaysia that used the
Casemix system. The latest updated data from a single year were
used (2011 for Malaysia and 2010 for Indonesia and the
Philippines). In total, there were 58 075, 134 500, and 50 791 hos-
pitalized patient records from Malaysia, Indonesia, and the
Philippines, respectively. All patient records were de-identiﬁed.
Pneumonia cases were identiﬁed by ICD-10 codes J10–J18
(Table 1). Patients were further categorized into CAP and HAP using
a simpliﬁed algorithm based on concepts similar to those used in
previous studies.10,32 Patients were categorized as having CAP if
they had (1) a primary diagnosis of pneumonia, or (2) a secondary
diagnosis of pneumonia with a respiratory condition as the
primary diagnosis. Meanwhile, patients were categorized as
having HAP if they had pneumonia in any of the secondary
diagnosis ﬁelds with a non-respiratory primary diagnosis.
Comorbidities recorded during the admission were also identiﬁed
(Table 2). Patients were placed into the CAP or HAP category based
on the above algorithm, then a descriptive analysis was performed
to calculate the incidence of CAP and HAP among the total number
of hospital discharges. Finally, for Malaysia, the population
incidence rate was estimated based on the catchment population
of the hospitals contributing the data. It was not possible to
ascertain the catchment populations for hospitals in the
Philippines and Indonesia, therefore population incidence rates
were not calculated.
Finally, CAP and HAP admissions were compared in terms of
cost per admission, mean LOS, case fatality rate (CFR), and
prevalence of comorbidities. To enable cost comparisons between
countries, average costs of admission were converted from local
currency units (Malaysian Ringgits, Indonesian Rupiah, and
Philippine Pesos) to USD based on the conversion rate in June
2013. Since the implementation of the Casemix system was new in
Indonesia and the Philippines, stakeholder discussions were heldTable 3
Incidence per 100 000 discharges and case fatality rates among hospitalized patients in
Malaysia discha
Item CAP HAP 
No. of discharges (n) - - 
No. of pneumonia cases (n) 2442 1270 
Incidence per 100 000 discharges 4205 2187 
No. of deaths (n) 102 324 
Proportion of pneumonia cases among discharged population (%) 4.2 2.
CFR among pneumonia cases (%) 4.2 25.
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; CFR, case fto better understand the reasons for the patterns seen and whether
they reﬂected experience in practice. The stakeholders attending
were those involved in the implementation of the Casemix system,
including representatives of the health insurance agencies and
ministries of health, and clinical experts from each country.
3. Results
Pneumonia was diagnosed in a large proportion of hospitalized
patients in the Philippines (19.9%) and a moderate proportion in
Malaysia (6.4%), but was diagnosed in a relatively low proportion
in Indonesia (1.5%) (Table 3). This corresponded to an incidence
rate among hospitalized patients of 14 245 CAP cases and
5615 HAP cases per 100 000 discharges in the Philippines,
4205 CAP and 2187 HAP cases per 100 000 discharges in Malaysia,
and 988 CAP and 538 HAP cases per 100 000 discharges in
Indonesia. The proportion of CAP cases was approximately two
times higher than the proportion of HAP cases in Malaysia and
Indonesia, and three times higher in the Philippines (Table 3). The
proportions of CAP and HAP cases among all hospital discharges
were high in the Philippines (14.2% and 5.6%, respectively). On the
other hand, the proportions of CAP and HAP were the lowest in
Indonesia (1.0% and 0.5%, respectively). The proportion of deaths
was higher in HAP compared to CAP: 25.5% vs. 4.2% in Malaysia,
11.3% vs. 1.8% in Indonesia, and 9.1% vs. 1.4% in the Philippines.
For Malaysia and the Philippines, the incidence of CAP per
100 000 discharges plotted against age group showed a perceptible
U-shaped curve compared to HAP, indicating a greater impact of
CAP on the youngest and the oldest age groups (Figure 1). This
pattern was most apparent for the data from the Philippines. This
U-shaped pattern was less apparent for Indonesia, as there were no
cases of CAP recorded within the age group 85 years and above. The
population incidence rate based on the catchment area of the
Malaysian hospitals was 159 per 100 000 for CAP and 83 per participating hospitals in the selected year
rges Indonesia discharges Philippines discharges
Total CAP HAP Total CAP HAP Total
58 075 - - 134 500 - - 50 791
3712 1329 723 2052 7235 2852 10 087
6392 988 538 1526 14 245 5615 19 860
426 24 82 106 100 260 360
2 6.4 1.0 0.5 1.5 14.2 5.6 19.9
5 11.5 1.8 11.3 5.2 1.4 9.1 3.6
atality rate.
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Figure 2. Pneumonia CAP and HAP incidence per 100,000 catchment population in
Malaysia according to age group.
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Figure 1. (a) Pneumonia CAP incidence per 100,000 discharges in Malaysia,
Indonesia and Philippines according to age group. (b) Pneumonia HAP incidence per
100,000 discharges in Malaysia, Indonesia and Philippines according to age group.
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the CAP incidence was 496 per 100 000 among children below
5 years of age, 64 per 100 000 for patients aged between 5 and
64 years, and 1305 per 100 000 for patients aged 65 years and
older. The estimated incidence of HAP was 33 per 100 000 among
children below 5 years of age, 53 per 100 000 for patients aged 5 to
64 years, and 717 per 100 000 for patients aged 65 years and older
(Table 4, Figure 2).
Figure 3 shows the CFR among HAP and CAP admissions across
age categories. Despite the incidence of CAP being highest in the
youngest and oldest age groups, the older age groups tended to
have higher CFRs related to pneumonia. This was most apparent for
the Philippines data. Overall, 48.6% of cases occurred in adults over
18 years of age, whereas 84% of deaths occurred in the same age
group (data not shown). The CFR was higher in HAP cases
compared to CAP cases in all three countries.Table 4
Estimated incidence rate of community-acquired pneumonia and hospital-
acquired pneumonia based on two participating hospitals in Malaysia (per
100 000 population)
Age group, years CAP HAP All pneumonia
Overall 159 83 242
<5 496 33 529
5–64 64 53 116
65 1305 717 2021
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia.Comorbidities among patients with CAP and HAP pneumonia
differed according to age group in each country (Supplementary
Material, Figures S1–S3). In all three countries, the most common
comorbidity among CAP cases was lung disease in young patients.
However, lung disease, cardiovascular disease, and diabetes were
more frequent in the older age groups. For HAP patients, the
prevalence of lung disease was even more prominent among the
younger age groups, while in the older age groups cardiovascular
disease and lung disease were once again common. For both types
of pneumonia, there was a dip in comorbidities seen in the oldest
age group.
In terms of admission costs, the total average cost per admission
for pneumonia was lowest in the Philippines (USD 254.3) and
highest in Malaysia (USD 1177.5) (Table 5). The average cost per
admission was slightly higher for HAP compared to CAP in each
country (Table 5). Due to the greater proportion of CAP cases
compared to HAP cases, it was estimated that CAP admissions cost
the hospitals more than HAP admissions. The total estimated costs
incurred for patients included in this dataset were USD 2.2 million
(CAP) and USD 1.9 million (HAP) in Malaysia, USD 1.6 million (CAP)
and USD 1.0 million (HAP) in Indonesia, and USD 1.8 million (CAP)
and USD 0.8 million (HAP) in the Philippines.
The overall average LOS was longer for the pneumonia
admissions in Malaysia (9.2 days) compared to Indonesia (8.0 days)
and the Philippines (6.6 days). Comparing LOS between CAP and
HAP, the results showed that HAP admissions were longer than
CAP admissions in Malaysia (10.2 days vs. 8.6 days) and in
Indonesia (7.9 days vs. 6.1 days). However, in the Philippines,
admission lengths were approximately the same: 6.2 days for CAP
and 6.9 days for HAP (Table 5).
4. Discussion
4.1. Comparison among countries
There were similarities as well as differences between the three
countries. One similarity was the U-shaped trend seen for CAP
incidence across age groups, although the pattern was less
prominent for Indonesia. This indicates a high incidence in young
children and the elderly and a low incidence in young and middle-
aged adults. This pattern has been described in previous studies.33–36
In all three countries, the proportion of CAP cases was higher than
the proportion of HAP cases; the highest ratio was seen in the
Philippines with a three-fold higher rate of CAP. On the other hand,
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Figure 3. (a) Pneumonia incidence per 100,000 discharges according to age groups
in Malaysia. (b) Pneumonia incidence per 100,000 discharges according to age
groups for Indonesia. (c) Pneumonia incidence per 100,000 discharges according to
age groups in Philippines.
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Similarly, LOS was higher for HAP than CAP in Malaysia and
Indonesia, but was almost the same duration for the two types of
pneumonia in the Philippines.Table 5
Length of stay and cost among hospitalized patients in participating hospitals
Malaysia discharges Indo
Item CAP HAP Total CAP
LOS (mean days) 8.6 10.2 9.2 
Cost per admission (mean USD) 927 1482 1178 
Estimated cost overall (USD) 2 263 734 1 882 140 4 372 736 1 60
CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia; LOS, length4.2. Explanations for the patterns seen
Some of the differences seen may be attributed to differences in
the individual country health systems and the implementation of
the Casemix system in the contributing hospitals. For instance, the
overall rate of pneumonia was very high in the Philippines but very
low in Indonesia. Also, the difference in CFR observed in CAP and
HAP varied quite markedly. The difference was most marked in
Malaysia (4.2% for CAP and 25.5% for HAP), followed by Indonesia
and the Philippines (Table 3).
Stakeholder meetings helped in gaining a better understand-
ing of the patterns seen. Stakeholders from Indonesia were
concerned about the low incidence rate reported for that
country, which did not reﬂect their clinical experience in
hospitals; they estimated that approximately 10% of all
discharges could be pneumonia-related. The stakeholders
believed that there may have been under-reporting of pneumo-
nia cases due to hospital preferences for a higher rate-paying
claim. Another explanation is that the newly launched social
insurance scheme covered patients from the lower socio-
economic groups who, due to family resource constraints and
cultural perceptions, did not bring their very elderly family
members to the hospital for treatment.
Stakeholders from the Philippines were concerned about the
low cost per admission reﬂected in the results of the study. The
stakeholders explained that the low cost may be due in part to the
relatively low ofﬁcial salaries of physicians and other hospital
employees. However, patients are often charged additional fees for
medical costs that are not covered by the social insurance system
and this additional fee is not recorded. The cost per admission was
estimated by the group to be approximately 40% higher than that
found in the study. The estimation of out-of-pocket fees brings the
estimate of the cost per pneumonia admission to USD 356. Despite
this higher amount, the cost per admission was still lower than
those for Malaysia and Indonesia and lower than that reported in a
recent study by Tumanan-Mendoza et al. (which reported a cost of
USD 852–2678 for moderate-risk CAP).18 It should be noted that
the results of Tumanan given here were based on the societal
perspective used in that study. For Malaysia, there was a notably
higher CFR for both CAP and HAP compared to Indonesia and the
Philippines. This was likely due to the hospitals in Malaysia that
contributed the data being tertiary academic referral centers. As
such, patients may have been more ill and may have had a greater
prevalence of comorbidities than those hospitalized in Indonesia
and the Philippines.
4.3. Comorbidities
The prevalence of comorbidities found in this study was similar
to those reported in previous studies that have shown patients
with comorbidities to be at greater risk of both CAP and
HAP.9,34,37,38 Among the most frequently reported comorbidities
were lung disease, cardiovascular disease, and diabetes mellitus.
The data on comorbidities were extracted from pneumonia cases
only and thus may reﬂect the general pattern of comorbidities. A
future study to ascertain the rates of pneumonia among patientsnesia discharges Philippines discharges
 HAP Total CAP HAP Total
6.1 7.9 8.0 6.2 6.9 6.6
1208 1373 1104 254 275 254
5 432 992 679 2 265 408 1 837 690 784 300 2 562 098
 of stay; USD, US dollars.
Table 6
Incidence of community-acquired pneumonia from previous studies
Study Study period Country Type of data used Age
(years)
Incidence
Low et al., 200716 1995–2004 Singapore Discharge diagnosis of pneumococcal disease
based on ICD-9 codes from the central claims
processing system
All Pneumococcal pneumonia:
4.53 per 100 000
Olsen et al., 200613 2002–2003 Sa Kaeo, Thailand Hospital admissions with pneumonia 0–75+ Pneumonia: 177–580 per 100 000
Kanlayanaphotporn et al., 200414 1999–2001 Sa Kaeo, Thailand Electronic surveillance data Overall Pneumonia: 211 per 100 000
Takahashi et al., 201315 2009–2010 Kha´nh Ho`a,
Central Vietnam
Adults aged 15 years and above with lower
respiratory tract infection
Overall CAP: 0.81 per 1000
Scott et al., 200441 2000–2002 New Zealand Hospital data of adults aged 15 years and older 15 CAP: 859 per 100 000
Giorgi Rossi et al., 200410 1997–1999 Lazio, Italy Hospital information system of the Lazio region Overall CAP: 158 per 100 000
Monge et al., 200142 1995–1996 Spain CAP identiﬁed using national surveillance
system for hospital data
Overall CAP: 160 per 100 000
Jokinen et al., 199334 1981–1982 Kuopio, Finland CAP; reported by physicians, pathologists,
autopsy and registry
Overall CAP: 11.6 per 1000
Aljunid et al., 2011 2011,
current study
Malaysia Casemix data from two academic centers Overall CAP: 159 per 100 000
HAP: 83 per 100 000
ICD, International Classiﬁcation of Diseases; CAP, community-acquired pneumonia.
S. Azmi et al. / International Journal of Infectious Diseases 49 (2016) 87–9392with and without comorbidities would be helpful to better
understand the impact of comorbidities.
4.4. Study limitations
There were several limitations to this study. The ﬁrst is related
to the administrative dataset used. The Casemix system is
relatively new and was used in different healthcare system
settings in the three countries studied. Other differences may be
due to actual underlying differences in costs, practices, and cultural
factors. Unlike Indonesia and the Philippines, only two hospitals
provided data for Malaysia. The types of hospitals included were
also different: the contributing hospitals in Indonesia and the
Philippines were private and public hospitals funded by social
insurance, whereas the hospitals in Malaysia were government-
funded academic hospitals.
In terms of methodology, the use of an administrative dataset in
combination with a simple algorithm may not reﬂect the incidence
as accurately as a prospective study or chart review method.
However, previous studies that have compared this method to
chart review still found it to be helpful in epidemiology
studies.32,39 The incidence of pneumonia among hospitalized
patients is higher than the incidence in the general population, as
indicated by the additional population incidence that was
calculated for Malaysia. The population incidence rates of CAP
and HAP for the two Malaysian hospitals, at 159 per
100 000 and 83 per 100 000, respectively, appear to be comparable
to rates in other countries as reported in previous studies
(Table 6).10,13–16,29,34,41,42 Unfortunately, it was not possible to
ascertain the catchment populations for the hospitals in Indonesia
and the Philippines and therefore it was not possible to estimate
the population incidence for these two countries.
4.5. General administrative data limitations
Aside from the limitations of the current dataset, there are also
biases inherent in the use of administrative databases. As noted by
Giorgi Rossi et al., capturing disease occurrence in a database
depends on a sequence of events beginning when the patient
perceives an illness and then presents him/herself to the
emergency room – steps that may be inﬂuenced by psycho-social
circumstances.10 Furthermore, the quality of the data entered into
the system is an important factor; the actual cause of illness as
assessed by the physician should be recorded, without reinterpre-
tation at the point of data entry. In addition, as has been mentioned
in previous publications using administrative and coded data, the
differences observed in terms of disease rates may be affected bythe differences in criteria adopted by hospitals in determining
the admission code,40 and by the frequency at which coders use the
codes incorrectly.39 These factors may have had an impact on
the present study. These issues may be resolved as the systems
become more established and as audits are performed as part
of the regular administrative processes to ensure accuracy; this
is done in developed countries where these systems are now
well-established.43,44
4.6. Conclusions
The results of this study show that there are differences in
disease burden between CAP and HAP, similar to the results of
previous studies performed in other countries.10,19,32,39 In all three
countries, CAP was found to be a frequent cause of hospitalization
in children under 5 years of age and those above the age of 50 years.
Although the cost per admission and the LOS for HAP tended to be
higher, the overall cost attributed to CAP was found to be greater,
due to the greater prevalence of CAP. The population incidence rate
calculated for Malaysia is consistent with the ﬁndings of earlier
studies. Despite the acknowledged limitations, it is believed that
this study contributes to the existing body of knowledge on
pneumonia. This study is also one of the ﬁrst to use administrative
data and a logical algorithm to ﬁnd differences between CAP and
HAP patterns in Southeast Asia. As the system becomes more
established and regular audits are made, the Casemix dataset could
be used in the future to provide greater clarity on pneumonia
patterns in the region. Meanwhile, other data owners, such as
social insurance providers and medical providers, should be
encouraged to share data with researchers for the purpose of
increasing knowledge of disease epidemiology in their respective
countries.27 A better understanding of the burden of pneumonia
and other diseases in Southeast Asia could help in planning
preventive strategies and improving clinical management.
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